Replies to post #111395 on Biotech Values

[DewDiligence]

Since you brought up Cramer, let me take the opportunity to point out how wrong Cramer was in asserting that Teva’s low-volume Copaxone was a “category killer” during his recent interview with Bill Marth (#msg-56322826). As usual, Cramer’s knowledge was about a millimeter deep, but at least he had the sense to realize, belatedly, that the threat to Teva’s Copaxone franchise and overall profitability is genuine.